Koninklijke Philips (PHG) said Tuesday that it has launched an international clinical investigation evaluating its ultra-low X-ray dose technology in coronary procedures.
The multicenter, randomized study will enroll 824 coronary artery disease patients in six hospitals in Spain, Czech Republic, and the US, with the aim of showing that the new technology can reduce overall patient radiation exposure without affecting coronary procedures, according to the company.
The trial evaluates radiation exposure, image quality, and procedural performance between Philips' technology and existing ClarityIQ technology, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.